North Carolina-based Vogenx, Inc. (Nasdaq: VOGX), a clinical-stage biopharmaceutical company developing treatments for metabolic conditions with no FDA-approved pharmacological options, priced its IPO at USD 13.00 per share — the high end of its stated range — raising gross proceeds of approximately USD 81.3 million.
The offering comprises 6,250,000 shares of common stock, all sold by Vogenx, with an overallotment option for up to an additional 937,500 shares. JonesTrading Institutional Services LLC acted as sole book-running manager. The company's shares were expected to begin trading on the Nasdaq Capital Market on August 12, 2026, with the offering expected to close August 13, 2026.
Vogenx disclosed total pre-IPO capital of approximately USD 11.5 million raised since inception through a Series A convertible preferred stock offering in 2021 and 2022 and a convertible promissory note in December 2025, according to an earlier S-1 filing. No crossover investors or concurrent private placements were disclosed.
The proceeds will help support clinical development of lead candidate mizagliflozin, an oral, minimally absorbed selective sodium-glucose transporter 1 (SGLT1) inhibitor that reduces and delays intestinal glucose absorption and lowers post-meal secretion of insulin and glucose-dependent insulinotropic polypeptide (GIP). Vogenx licensed exclusive worldwide rights to mizagliflozin, excluding Japan, Korea, and Taiwan, from Japan-based Kissei Pharmaceutical in December 2021 under an agreement that includes approximately USD 27 million in development and regulatory milestones plus a high single-digit royalty on net sales, the company stated.